Stay informed
Dropdown menu

CURRENT TGCT TREATMENT OPTIONS HAVE LIMITATIONS

TGCT symptoms are unpredictable. Because symptoms don't affect patients the same way every day, treatment planning and decision-making can be difficult while the tumor continues to cause damage. At the same time, current treatment options have advantages and disadvantages that need to be considered.1-6

CURRENT TGCT TREATMENT 
OPTIONS HAVE PROS AND CONS

tgct-image

CURRENT TGCT TREATMENT OPTIONS HAVE LIMITATIONS

Advantages

  • Reduces the size of the tumor and may remove it completely, which helps with symptoms3,7
  • Possibility that a single procedure may resolve the condition7

Disadvantages

  • May require a long postoperative recovery time8
  • Risk of recurrence, which varies by TGCT subtype1:
    • 72% chance of recurrence with diffuse TGCT
    • 34% chance of recurrence with localized TGCT

Advantages

  • Target and block CSF-1 receptors, a main driver of TGCT9
  • May help with symptoms9

Disadvantages

  • Don’t reduce the tumor in many patients5,6,10
  • Require regular dosing (per Prescribing Information)5,6

Surgery is the standard first-line approach for patients with resectable TGCT—at the same time, the landscape is evolving rapidly with the investigation of different treatment approaches4,11

SIGN UP FOR MORE INFORMATION ABOUT TGCT

SIGN UP FOR MORE INFORMATION ABOUT TGCT

Get the latest updates from EMD Serono

STAY INFORMED

REFERENCES

1. Stern S, McKenzie PF, Bernthal N, et al. Localized and diffuse tenosynovial giant cell tumor: real-world results from a patient observational registry. Future Oncol. 2025;21(12):1501-1510. doi:10.1080/14796694.2025.2488635 2. Nishida Y, Tsukushi S, Nakashima H, et al. Osteochondral destruction in pigmented villonodular synovitis during the clinical course. J Rheumatol. 2012;39(2):345-351. doi:10.3899/jrheum.110730 3. Gelhorn HL, Ye X, Speck RM, et al. The measurement of physical functioning among patients with Tenosynovial Giant Cell Tumor (TGCT) using the Patient-Reported Outcomes Measurement Information System (PROMIS). J Patient Rep Outcomes. 2019;3(1):6. doi:10.1186/s41687-019-0099-0 4. Stacchiotti S, Dürr HR, Schaefer IM, et al. Best clinical management of tenosynovial giant cell tumour (TGCT): a consensus paper from the community of experts. Cancer Treat Rev. 2023;112:102491. doi:10.1016/j.ctrv.2022.102491 5. Romvimza [package insert]. Waltham, MA: Deciphera Pharmaceuticals, Inc. 6. Turalio [package insert]. Basking Ridge, NJ: Daiichi Sankyo, Inc; 2025. 7. TGCT Support. Treatment. Accessed August 27, 2025. https://www.tgctsupport.org/treatment.html. 8. TGCT Support. Recovery. Accessed August 27, 2025. https://www.tgctsupport.org/recovery.html. 9. Stern S, Hall A, Bauer S, et al. Patient-friendly version of tenosynovial giant cell tumor (TGCT): a consensus paper from the community of experts. Accessed August 27, 2025. https://www.tgctsupport.org/uploads/1/3/5/7/135702737/tgct-2023-patient-consensus-paper.pdf. March 2023.  10. Aykan NF, Özatlı T. Objective response rate assessment in oncology: current situation and future expectations. World J Clin Oncol. 2020;11(2):53-73. doi:10.5306/wjco.v11.i2.53 11. Data on file. 

Footer Border
Footer Border

©2025 Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved.

EMD Serono is a Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada.

200 Pier 4 Blvd, Boston, MA 02210

This website is intended only for residents of the United States. Use and access of this site are subject to the terms and conditions set out in our Legal Statement and Privacy Policy.

US-NONOTGCT-00007 10/25

THIS SITE IS INTENDED FOR US HEALTHCARE PROFESSIONALS

THIS SITE IS INTENDED FOR US HEALTHCARE PROFESSIONALS

I AM A HEALTHCARE PROFESSIONAL

I AM NOT A HEALTHCARE PROFESSIONAL